<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653571</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0760</org_study_id>
    <nct_id>NCT04653571</nct_id>
  </id_info>
  <brief_title>CASPR2 Encephalitis Initial Symptoms</brief_title>
  <acronym>iniCASPR2</acronym>
  <official_title>Defining the Initial Clinical Symptoms and Characterizing Those Leading to the Discovery of CASPR2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Auto-immune encephalitides involve auto-antibodies targeting the central nervous system, and&#xD;
      particularly the synapse and its structure, such as protein CASPR2.&#xD;
&#xD;
      CASPR2 antibody-associated auto-immune encephalitides lead to an inflammation of the limbic&#xD;
      system and generate focal temporal seizures and cognitive impairment. Most patients are&#xD;
      initially hospitalized because of the temporal seizures (Joubert et al., JAMA Neurology&#xD;
      2016). However, many already show at that time cognitive impairment, which has failed to&#xD;
      elicit the appropriate investigations, therefore delaying the diagnosis.&#xD;
&#xD;
      The study will hence investigate precisely the initial, sometimes neglected, clinical&#xD;
      symptoms and those leading to the diagnosis, in the cohort of patients suffering from a&#xD;
      CASPR2 antibody-associated encephalitis, from the French reference center on paraneoplastic&#xD;
      neurological diseases and autoimmune encephalitis.&#xD;
&#xD;
      This way, the study aims to delineate the symptoms that should trigger suspicions of a CASPR2&#xD;
      antibody-associated encephalitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Initial cognitive impairment or clinical presentation of first epileptic seizures.</measure>
    <time_frame>8 months</time_frame>
    <description>The retained information will depend on the very first declared symptom: if the patient first showed focal seizures, we will precise the clinical presentation of this seizure. On the other hand, if the patient first showed cognitive symptoms, we will best define this impairment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">51</enrollment>
  <condition>CASPR2-Antibody</condition>
  <condition>Encephalitis Autoimmune</condition>
  <condition>Paraneoplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>CASPR2 encephalitis</arm_group_label>
    <description>Cohort of patients with a CASPR2 antibody-associated auto-immune encephalitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CASPR2 encephalitis</intervention_name>
    <description>Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.</description>
    <arm_group_label>CASPR2 encephalitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a CASPR2 antibody-associated auto-immune encephalitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive CASPR2-Ab in serum and/or CSF tested by immunohistochemistry on mouse brain&#xD;
             slices and confirmed by cell-based assay (CBA) of HEK293 cells expressing CASPR2.&#xD;
&#xD;
          -  Diagnosis and follow-up in France&#xD;
&#xD;
          -  From 18 to unlimited age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients CASPR2-IgG negative in serum and CSF&#xD;
&#xD;
          -  Foreign follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme HONNORAT, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de neuro-oncologie, Hôpital neurologique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme HONNORAT, Pr</last_name>
    <phone>4 72 35 78 08</phone>
    <phone_ext>+33</phone_ext>
    <email>jerome.honnorat@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marine VILARD, CRA</last_name>
    <phone>4.27.85.54.60</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.villard@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Neuro-Oncologie, Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine Villard, CRA</last_name>
      <phone>4.27.85.54.60</phone>
      <email>Marine.villard@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jérôme Honnorat, Pr</last_name>
      <phone>4.27.85.54.60</phone>
      <phone_ext>+33</phone_ext>
      <email>jerome.honnorat@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibody ; auto-immune encephalitis ; paraneoplastic syndrome ; CASPR2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraneoplastic Syndromes</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

